JAIDS Journal of Acquired Immune Deficiency Syndromes · 2002 · 421 citations · 9 references
MedicineCardiologyInfectious DiseasesCardiovascular PharmacotherapyHiv PreventionPreventive CardiologyAntiretroviral TherapyAntiviral PharmacologyAntiviral TherapyCardiovascular DiseaseCoronary Artery DiseaseIschemic Heart DiseaseViral Protease Inhibition
There is ongoing concern that protease inhibitors may increase coronary heart disease risk in HIV‑infected patients, and other HIV‑related mechanisms may also contribute to elevated CHD and MI risk. The study examines CHD and MI hospitalization rates before and after PI use and ART among HIV‑positive members of Kaiser Permanente Northern California. The authors used observational data to compare CHD and MI hospitalization rates before and after PI and ART use in HIV‑positive patients and against HIV‑negative controls. Over a median 4.1‑year follow‑up, age‑adjusted CHD and MI hospitalization rates did not differ significantly before versus after PI or ART use, but HIV‑positive patients had higher CHD (6.5 vs 3.8) and a trend toward higher MI rates (4.3 vs 2.9) compared with HIV‑negative members; overall, the data suggest PIs and other ARTs do not yet increase CHD or MI hospitalizations, though longer follow‑up is needed.
Summary: There is continued concern about protease inhibitors (PIs) causing increased risk of coronary heart disease (CHD) in HIV-infected patients. This ongoing observational study examines CHD and myocardial infarction (MI) hospitalization rates among HIV-positive members of the Kaiser Permanente Medical Care Program of Northern California, before and after PI use, and before and after any antiretroviral therapy (ART). Also, CHD and MI hospitalization rates among HIV-infected members are compared with members not known to be HIV-positive. With 4.1 years' median total follow-up, age-adjusted CHD and MI hospitalization rates were not significantly different before versus after PIs (6.2 vs. 6.7 events per 1000 person-years); or before versus after ART (5.7 vs. 6.8). However, comparing HIV-positive and -negative members, the CHD hospitalization rate was significantly higher (6.5 vs. 3.8, p = .003), and the difference in the MI rate also was higher (4.3 vs. 2.9, p = .07). Differences between HIV-positive and -negative members in the CHD risk factors measured were mixed, and the overall clinical significance of these differences is uncertain. Our data suggest that PIs and other antiretroviral therapies do not yet increase CHD or MI hospitalizations among HIV-infected individuals; however, longer follow-up is needed. Other HIV-related mechanisms may be at work, causing increased CHD and MI risk among all HIV-infected persons.
9
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson, Ralph B. D’Agostino, Daniel Levy et al. · Circulation · 1998 · 9.6K citations
An updated coronary risk profile. A statement for health professionals.
Keaven M. Anderson, P W Wilson, Patricia M. Odell et al. · Circulation · 1991 · 1.9K citations